Trilaciclib - G1 Therapeutics

Drug Profile

Trilaciclib - G1 Therapeutics

Alternative Names: G1T 28; G1T28-1

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Chemoprotectants; Cyclohexanes; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrimidinones; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer
  • Preclinical Cancer
  • No development reported Myelosuppression

Most Recent Events

  • 05 Mar 2018 Efficacy and adverse events data from a Phase-II clinical trials in Small cell lung cancer (First-line therapy, Combination therapy, Newly diagnosed) released by G1 Therapeutics
  • 21 Feb 2018 G1 Therapeutics completes enrolment in phase II trial for Small cell lung cancer (First-line therapy, Combination therapy, Newly diagnosed)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Netherlands (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top